Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab monotherapy in dMMR/MSI-H solid tumors
NCT04326829Phase 2Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Jul 2020
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of iparomlimab in solid tumor, colorectal carcinoma (CRC), sponsored by Qilu Pharmaceutical. Status: unknown.
02
Drugs
iparomlimab
03
Conditions
solid tumorcolorectal carcinoma (CRC)
Beyond the preview
Go deeper on NCT04326829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04326829.